$RGBP HemaXellerate Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
Fat stem cell based product to treat bone marrow that has been damaged Bone marrow damage occurs from radiation, chemo, or chronic conditions HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.